The main objective of this review is to highlight and explore the inter-relationship and the functioning of the intellectual property right in the pharmaceutical and biotechnology industry. The rising tide of patent applications can be witnessed globally in this industry as the need for such protection and licensing has become imperative so as to safeguard the rights of the inventor and also to encourage and promote new talents, inventions and innovations which can be a boon for the economy. The field of biotechnology is an upcoming science which is still at the initial stage of establishing a foundation but it promises a revolution in the fields of medicine, agriculture, pharmaceuticals and industrial sector amongst other sectors of the economy along with contribution to the GDP growth.
INTRODUCTION
Intellectual property refers to the exclusive rights granted by the State over creations of the human mind, in particular, inventions, literary and artistic works, distinctive signs and designs used in commerce. Intellectual property is divided into two main categories: industrial property rights, which include patents, utility models, trademarks, industrial designs, trade secrets, new varieties of plants and geographical indications; and copyright and related rights, which relate to literary and artistic works.
Industrial property (IP) rights are extremely important for the pharmaceutical industry. The use of the IP system by SMEs in the pharmaceutical industry depends largely on the business strategy of a company, its size, resources, innovative capacity, competitive context and field of expertise. Research-based, innovation-led companies that seek to develop new drugs improve or adapt existing drugs or develop new pharmaceutical/medical equipment or processes, tend to rely heavily on the patent system to ensure they recover the investments incurred in research and development. Companies that rely on licensing in or licensing out of pharmaceutical products will need to be knowledgeable about the patent system to so that they are able to negotiate fair and balanced licensing contracts. SMEs in the pharmaceutical industry may use the wealth of information contained in patent documents as a crucial input to their R&D work, to get ideas for further innovation, to ensure their "freedom to operate" or to find out when a patent is due to expire opening the door for the introduction of generics.
Confidential information, protected as trade secrets, is also important for many companies, as is the valuable know-how or undisclosed test data relating to new or improved drugs.
Understanding the trademark system is important for companies selling branded products.
Industrial designs, plant variety protection and copyright and related rights are generally less relevant to most SMEs in the pharmaceutical sector but this could vary depending on the product line and strategy of each company. .
(a) Copyrights and related rights
In the area of copyright and related rights (i.e. rights of performers, producers of phonograms and broadcasting organizations), the Agreement requires compliance with the substantive provisions of the Berne Convention. Computer programmes are to be protected as literary works, the term of protection for copyrights and right of performers and producers of phonograms is to be no less than 50 years. In case of broadcasting organisations, however, the term of protection is to be at least 20 years. India is already a signatory to the Berne Convention and our laws conform to the provisions of the Convention. India's copyright law has been amended and in some ways exceeds the requirements of the TRIPS Agreement, for example, on the period for copyright protection (which is 60 years in India). The law was amended in December 1999 to grant 25-year term of protection for neighbouring rights.
(b) Trademarks
The Trade and Merchandise Marks Act 1958 was in its essential features in accordance with TRIPS, except that it did not cover service marks in its scope. This has been done by replacing it with the Trademarks Act 1999. We are now fully compliant with our TRIPS obligations.
(c) Geographical Indication
The Agreement contains a general obligation that parties shall provide the legal means for interested parties to prevent the use of any means in the designation or presentation of a good that indicates or suggests that the good in question originates in a geographical area other that the true place of origin of the good. We currently provide protection to geographical indications through passing off action in courts or through certification marks. However, to provide better protection to geographical indications a new law "The Geographical Indication of Goods (Registration & Protection) Act, 1999 has since been enacted.
(d) Industrial Designs
Obligations envisaged in respect of industrial designs are that independently created designs that are new or original shall be protected. There in an option to exclude from protection, designs dictated by technical or functional consideration, as against aesthetic consideration which constitutes the coverage of industrial designs.
(e)Patents
The basic obligation in the area of patents is that, inventions in all fields of technology whether products or processes shall be patentable if they meet the three tests of being novel, involving an inventive step and being capable of industrial application. In addition to the general security exception, which applies to the entire TRIPS Agreement, specific exclusions are permissible from the scope of patentability. These are available in the areas of inventions whose commercial exploitation is to be prevented to protect public order or morality, human, animal plant life or health or to avoid serious prejudice to the environment. In addition, we can exclude from patentability diagnostic, therapeutic and surgical methods for the treatment of human and animals, plants and animals other than microorganisms, and essentially biological process for the production of plants and animals other than non-biological processes.
To meet our TRIPS obligations as on 1.1.2000, the Patents (Second Amendment) Bill, 1999 has been introduced in the Parliament in December 1999 and is before the Joint Committee of theHouses.
In respect of plant varieties, there is an obligation to provide for protection either by patents or by an effective sui generis system or by any combination thereof. The Agreement does not spell out the elements of an effective sui generis system and it is left to each Government to determine the elements, which could be deemed to be providing effective protection. A decision has been taken to put in place a sui generis system as it is perceived to be in our national interest. A Bill in this regard is before the Joint Committee of the Houses of the Parliament.
Patentable subject matter-
Under many national laws, patentable subject matter is defined negatively, i.e. by providing a list of what cannot be patented. However, there are important differences between countries in terms of what may represent unpatentable subject matter. For example, patent legislation in some countries includes some of the following as unpatentable subject matter:
 Discoveries and scientific theories;
 Aesthetic creations (which may be protected by industrial designs);
 Schemes, rules and methods for performing mental acts;
 Newly discovered substances as they naturally occur in the world;
 Inventions the exploitation of which is contrary to "public order" or morality;
 Diagnostic, therapeutic and surgical methods of treatment for humans or animals (but not products for use in such methods);
 Plants and animals other than microorganisms, and essentially biological processes for the production of plants or animals other than non-biological and microbiological processes.
In the pharmaceutical industry, types of inventions that are patentable in many countries (as long as the other criteria are met) include new pharmaceutical compounds, new or improved products for diagnostics, new dosage forms of known therapeutics, microorganisms, novel combinations of known compounds, processes and methods used for manufacturing a particular product, new and/or improved manufacturing equipment and new and/or improved drug delivery mechanisms or technologies. The list is by no means exhaustive and not all of the above are patentable in all countries.
The novelty requirement
An invention is new (or novel) if it does not form part of the prior art. The prior art is, in general, all the knowledge that has been made available to the public prior to the filing date (or priority date) of the relevant patent application or (in the United States) prior to when the invention was "made". The definition of "prior art" differs from country to country. In many countries, any invention made available to the public anywhere in the world in written form, by oral communication, by display or through use constitutes the prior art. Thus, in principle, the publication of the invention in a scientific journal, its presentation in a conference, its use in commerce or its display in a company's catalogue before the filing date (or priority date) of the application claiming that invention would constitute acts that could destroy the novelty of such invention and render it not patentable.
It is important to note, however, that in some countries, there is a grace period (usually of 6 or 12 months from the public disclosure of the claimed invention by the inventor) during which an applicant may file an application without the novelty being destroyed by such disclosure.
The inventive step/non-obviousness requirement
An invention is considered to involve an inventive step (or to be non-obvious) when, having regard to the prior art, the invention would not have been obvious to a person skilled in the particular field of technology. The non-obviousness requirement is meant to ensure that patents are not granted on developments that a person skilled in the relevant art could easily deduce from what already exists.
Industrial applicability/utility requirement
To be patentable, an invention must be capable of being used in industry (or meet the utility requirement). This means that the invention cannot be a mere theoretical phenomenon, but it must be useful and provide some practical benefit. The term "industry" is used in the broad sense, meaning anything distinct from purely intellectual or aesthetic activity, and includes, for example, agriculture. In biotechnology, the utility requirement has become particularly important in the context of the patenting of genetic sequences over which possible industrial applications are unclear. Some countries require that the utility be well established and asserted for the claimed invention in a specific, substantial and credible manner.
The disclosure requirement
According to the applicable national or regional legislation of most countries a patent application must disclose the invention in a manner sufficiently clear and complete for the invention to be carried out by a person skilled in the specific technical field (enabling disclosure requirement). For example, a patent application for a new pharmaceutical product, must include enough practical information so that anyone familiar with the relevant technical field is able to follow the indicated steps and replicate and produce an effective copy of it. In some countries, patent legislation requires the applicant to disclose the "best mode" for practicing the invention. For inventions involving microorganisms, many countries require that, if the microorganism is not accessible to the public and the claimed invention cannot be described in such a way to comply with the enabling disclosure requirement without having access to that microorganism, such microorganism be deposited at a recognized depositary institution, which is capable of maintaining the microorganism in a live culture for a prescribed period of time.
Patents in the life sciences
To comply with requirements under the TRIPS Agreement of the World Trade Organization, most countries allow for the patenting of microorganisms and, as explained above, often require the deposit of a sample of the microorganism at a recognized depositary institution when necessary to comply with the enabling disclosure requirement. Some countries exclude plants and animals (other than microorganisms) from patentability. Biological materials that have been purified and isolated from their natural environment or produced by means of a technical process are patentable in many jurisdictions. National patent law in many countries may also list some specific types of inventions that are excluded from patentable subject matter, such as processes for cloning human beings or processes for modifying the germ line genetic identity of human beings.
Depending on the country, plant varieties are protected either by the patent system, by a sui generis protection system for new varieties of plants or by a combination of the two.
Patents on improved variations and new uses
In many countries, improvements made to existing products are patentable, as are also new uses of a patented product, provided all the patentability requirements are met. In the 
(g) Protection of undisclosed information
The Agreement provides in this area that natural and legal persons shall have the possibility of preventing information lawfully within their control from being disclosed to, acquired by or used by others without their consent in a manner contrary to honest commercial practices.
Further, parties are required to protect against unfair commercial uses, undisclosed or other data obtained as a condition of approving the marketing of pharmaceutical or of agricultural chemical products.
INDIAN PHARMACEUTICAL INDUSTRY
The Indian pharmaceutical sector has come a long way, being almost non-existent before 1970 to a prominent provider of healthcare products, meeting almost 95 per cent of the country's pharmaceuticals needs.
The Industry today is in the front rank of India's science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. It ranks very high in the third world, in terms of technology, quality and range of medicines manufactured. From simple headache pills to sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously.
Playing a key role in promoting and sustaining development in the vital field of medicines, Indian Pharma Industry boasts of quality producers and many units approved by regulatory authorities in USA and UK. International companies associated with this sector have stimulated, assisted and spearheaded this dynamic development in the past 53 years and helped to put India on the pharmaceutical map of the world.
The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units with severe price competition and government price control. It has expanded drastically in the last two decades.
There are about 250 large units that control 70 per cent of the market with market leader holding nearly 7 per cent of the market share and about 8000 Small Scale Units together which form the core of the pharmaceutical industry in India (including 5
Central Public Sector Units). These units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption by patients and about 350 bulk drugs, i.e., chemicals having therapeutic value and used for production of pharmaceutical formulations.
Following the de-licensing of the pharmaceutical industry, industrial licensing for most of the drugs and pharmaceutical products has been done away with. Manufacturers are free to produce any drug duly approved by the Drug Control Authority. Technologically strong and totally self-reliant, the pharmaceutical industry in India has low costs of production, low R&D costs, innovative scientific manpower, strength of national laboratories and an increasing balance of trade.
The total Indian production constitutes about 13 per cent of the world market in value terms and, 8 per cent in volume terms.
The per capita consumption of drugs in India, stands at US$3, is amongst the lowest in the world, as compared to Japan-US$412, Germany-US$222 and USA-US$191.
Current Status 4
India's US$ 9.4 billion pharmaceutical industry is growing at the rate of 14 percent per year.
It is one of the largest and most advanced among the developing countries.
The Indian pharmaceutical industry can reach a market size of US$ 11. The focus of the Indian pharma companies is also shifting from process improvisation to drug discovery and R&D. the Indian companies are setting up their own R&D setups and are also collaborating with the research laboratories like CDRI, IICT etc.
Emerging Trend
The Indian pharmaceutical industry is now discovering new opportunities of growth in • The growing population of over of a billion However, Espicom's market projections forecast more modest but stable annual market growth of around 7.2 per cent, putting the market at US$ 11.6 billion by 2009.
Revenue from Export-India accounts for less than two per cent of the world market for pharmaceuticals, with an estimated market value of US$10.4 billion in 2007 at consumer prices, or around US$9 per capita. India currently represents just U.S. $6 billion of the $550 billion global pharmaceutical industry but its share is increasing at 10 percent a year, compared to 7 percent annual growth for the world market overall. Also, while the Indian sector represents just 8 percent of the global industry total by volume, putting it in fourth place worldwide, it accounts for 13 percent by value, and its drug exports have been growing 30 percent annually. Cipla, Nicholas Piramal, Ranbaxy, Zydus Cadila, Dr.
Reddy's are the few Indian pharmaceutical companies, which are known at the global level due to their quality products.
BIOTECHNOLOGY AND ITS GROWING IMPORTANCE
Biotechnology is a field of applied biology that involves the use of living Since India depicts an interesting demographic profile and a large agricultural base, India being mainly an agrarian economy, it also affords a large market base for new biotechnology products since being a developing economy it has a wide scope for the utilization and the implementation of these resources because of its cost competitive manpower, well developed and integrated scientific infrastructure and is globally recognized as a producer of low cost, high quality bulk drugs and formulations and other biotech products and services which holds a promising market 7 
INTELLECTUAL PROPERTY RIGHTS AND THE CHALLENGES TO INDIAN PHARMACEUTICAL INDUSTRY 9
The Indian pharmaceutical industry has changed remarkably over the last 50years, from being traders in imported drugs in the fifties, to major bulk drug producers by the eighties. the country on the date of filing, at the time when patent is granted or rejected.
parties decide to grant the patent.
for five years or until patent is granted or rejected, whichever period i
Granting of exclusive marketing rights is subject to three conditions:
(i) product patent for the invention has been granted by another mem
(ii) market approval is obtained in such other member country; and (iii) market approval from the country/member granting exclusive marketing right is granted.
Before the recent amendment Section 5 of the Indian Patents Act, 1970 Expressly prohibited product patents and only permitted process patent. After the implementation of TRIPS, the Patents (Amendment)Act, 2005 repealed it and therefore gave way to product patents as well.
The difference between process patent and product patent is that under a process patent, medicine or drugs which have been patented can be manufactured by another manufacturer but by using a different process. However, in a product patent drugs which have been (f) Some exemptions have been provided for certain drugs from the price control-new drugs developed in India through product patent, process patent and new drug delivery systems would be exempted from price control for 5 years. This will boost R&D in India.
Simultaneously, vaccines and biological drugs, drugs for sale to hospitals only, drugs whose uterization and better monitoring. 
Global IP regulations
ria -being novel, involving an inventive step and being capable of industrial application.
protect public order, human, animal and plant welfare, and to avoid environmental damage.
Both Japan and Mexico saw a tripling of US pharmaceutical investments and R&D after they improved patent laws. In fact, over the past years, the stumbling block for global investors, looking for tie-ups with Indian firms has been the perception that India's IPR norms are too lenient. "The prime reason Singapore is chosen over India is because they protect Intellectual Property Rights. Companies take their R&D and clinical trial operations to Singapore because they see clarity in regulation, besides other finan Even though, the WTO TRIPS agreement provides a foundation for IPR protection, enforcement is lacking in many parts of the world. The basic obligation in the area of patents is that inventions in all fields of technology, whether products or processes, shall be patentable if they meet three crite Additionally, a patent can be granted for any invention that meets the patentability conditions in all fields of technology, irrespective of the place of invention. Over and above, in the general security exception, which applies to the entire TRIPS Agreement, only specific exclusions are permissible from the scope of patentability. Such exclusions span research areas, whose commercial exploitation should be prevented to Biotechnology patent applications experience numerous restrictions, primarily, due to the undefined scope and complex nature of the technology. Deciding the scope of patent protection for inventions is a difficult task, as it raises a number of technical and ethical issues. To begin with, biotechnology is an intimidating amalgamation of biology and chemistry and claim interpretations. They force a judge or patent examiner to grapple with rather fundamental issues, such as the significance of the term 'human' when describing a protein. Next, it raises important policy questions, such as, the degree to which a legal monopoly should be granted to an innovator, whose significant contribution could be diminished by the consequent development of a competitor product or technique.
Article 27 of TRIPS agreement concerns the availability, scope and use of IPR in making distinctions between material produced by biological processes and by non-biological routes;
only the latter is considered patentable. Natural material of any kind is not patentable and article 27(3) (b) makes it clear that member states are entitled to exclude plants and animals but not micro-organisms from the scope of patentability. However, it is unclear whether TRIPS permits member states to exclude biological substances like genes and cells.
Currently, two schools of thought exist. The first school states that there is no scientific basis to support the patenting of genes and genomes, which are discoveries at best, while the second school states that characterisation of genes is not straightforward, so it does constitute an inventive step and therefore should be patentable. However, despite the apparent Currently, The United that, in turn, would improve patent quality, efficiency and will be necessary for international harmonisation of rules.
n to twenty years.
With this change, India fulfilled part of its commitment to the international community by compared to China which ranks second), in funding given to countries outside the US by the omplete the legal IP framework. The National Biotech Policy provides a framework and strategic direction to different sectors in order to accelerate the pace of development of anpower, which encourages science graduates to pursue law for a better understanding of IPR related issues and inclusion of the same in the curriculum of law
IP scenario in India
India needs to implement strong patent legislation, data exclusivity, and improve IPR infrastructure and enforcement in order to achieve its potential as an R&D powerhouse. The Building on the enormous investment already made by the research-based pharmaceutical industry, copycat drugs can lower drug prices, but they do nothing to guarantee that new drugs will be available when they are needed. Copycat drugs do nothing to ensure that scientific innovation translates into new treatments that may be less toxic and more effective.
Rather, they reduce incentives to research and thus discourage new products. And make no mistake: The manufacturers of generic or copycat drugs are not in business to be generous; they, too, are reaping profits. Their profits, however, are not being used to further scientific knowledge and find new cures.
Patents are not the problem that people assume them to be, either. A recent study published in Health Affairs found that "in 65 low-and middle-income countries, where four billion people live, patenting is rare for 319 products on the World Health Organization's Model List of Essential Medicines. Only 17 essential medicines are patentable, although usually not actually patented." If this large amount of life-saving drugs is either off-patent (meaning that the company that originally invented them no longer has an exclusive claim because the patent has expired) or not patented, then patents cannot be the problem in getting drugs to people.
Price is not always the issue, either. When people cite prices as a problem, they often are comparing apples and oranges. Prices include various factors: training of health care personnel in the use of the drug, explanatory materials to make it safer for the consumer, even shipping and handling can be included or not. If one drug seems cheaper but shipping costs are not included, the effective cost may be identical to that of a patented drug. Certainly, a government-sponsored drug company can provide lower prices to the citizens of that country, since the government is paying a large percentage of the actual cost.
There are issues that need to be addressed, including how to encourage even more innovation, and ensuring health care for all -especially for the welfare of the poor.
